Abstract
Glucosylceramide-laden tissue macrophages in Gaucher patients secrete large quantities of chitotriosidase and CC chemokine ligand 18 (CCL18), resulting in markedly increased plasma levels. We have comparatively investigated the occurrence of both parameters in plasma and urine samples of Gaucher patients. Chitotriosidase was high in urine samples of some symptomatic patients, but elevations did not correlate with increased plasma concentrations. Urinary chitotriosidase was particularly high in a patient with severe kidney involvement and local storage cell infiltration. Urinary levels of CCL18 were also highly elevated in samples from Gaucher patients as compared to controls. The median value of the CCL18/creatinine ratio in urine samples of 31 Gaucher patients was 143.3 pg/μmol (range 32–551) and in those of 12 normal subjects was 4.1 pg/μmol (range 1.3–6.8). In sharp contrast to chitotriosidase, increases in the low-molecular-mass chemokine CCL18 in urine and plasma specimens of Gaucher patients correlated well. A correlation was also observed for reductions in urinary and plasma CCL18 following therapy. It is concluded that assessment of urinary CCL18 of Gaucher patients gives insight into the total body burden on Gaucher cells, whereas that of chitotriosidase does not. Urinary chitotriosidase appears rather to be a reflection of renal pathology.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aerts JM, Donker-Koopman WE, Koot M, et al (1986) Comparison of the properties of a soluble form of glucocerebrosidase from human urine with those of the membrane-associated tissue enzyme. Biochim Biophys Acta 863: 63–70.
Aerts JM, Hollak C, Boot R, et al (2003) Biochemistry of glycosphingolipids storage disorders: implications for therapeutic intervention. Philos Trans R Soc Lond B Biol Sci 358: 905–914.
Aguilera B, Ghauharali-Van Der Vlugt K, Helmond MT, et al (2003) Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase. J Biol Chem 278: 40911–40916.
Baldellou A, Andria G, Campbell PE, et al (2004) Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 163: 67–75.
Barton NW, Brady RO, Dambrosia JM, et al (1991) Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 324: 1464–1470.
Beutler E, Grabowski GA (2001) Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 3635–3668.
Boot RG, Renkema GH, Strijland A, et al (1995) Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. J Biol Chem 270: 26252–26256.
Boot RG, Renkema GH, Verhoek M, et al (1998) The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem 273: 25680–25685.
Boot RG, Blommaart EF, Swart E, et al (2001) Identification of a novel acidic mammalian chitinase distinct from chitotriosidase. J Biol Chem 276: 6770–6778.
Boot RG, Verhoek M, De Fost M, et al (2004) Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 103: 33–39.
Boven LA, van Meurs M, Boot RG, et al (2004) Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 122: 359–369.
Cox TM (2003) Future perspectives for glycolipid research in medicine. Philos Trans R Soc Lond B Biol Sci 358: 967–973.
Cox T, Lachmann R, Hollak C, et al (2000) Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT918) to decrease substrate biosynthesis. Lancet 355: 1481–1485.
Cox TM, Aerts JM, Andria G, et al (2003) The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 26: 513–526.
Deegan PB, Moran MT, McFarlane I, et al (2005) Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis 35: 259–267.
Hollak CEM, van Weely S, van Oers MHJ, et al (1994) Elevated plasma chitotriosidase: a novel biochemical hallmark of Gaucher disease. J Clin Invest 93: 1288–1292.
Hollak CE, Maas M, Aerts JM (2001) Clinically relevant therapeutic endpoints in type I Gaucher disease. J Inherit Metab Dis 24(Supplement 2): 97–105.
Moran MT, Schofield JP, Hayman AR, et al (2000) Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood 96: 1969–1978.
Platt FM, Jeyakumar M, Andersson U, et al (2001) Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy. J Inherit Metab Dis 24: 275–290.
Slot C (1965) Plasma creatinine determination. A new and specific Jaffe reaction method. Scand J Clin Lab Invest 17: 381–387.
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicating editor: Verena Peters
Competing interests: None declared
Rights and permissions
About this article
Cite this article
Boot, R.G., Verhoek, M., Langeveld, M. et al. CCL18: A urinary marker of Gaucher cell burden in Gaucher patients. J Inherit Metab Dis 29, 564–571 (2006). https://doi.org/10.1007/s10545-006-0318-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10545-006-0318-8